Compare BridgeBio Pharma Inc (BBIO) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Direxion Daily TSLA Bull 2X Shares trades at $12.21. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| BBIO | TSLL | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $23.03 |
52-Week Low | $44.81 | $10.29 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
TSLL is trading at $12.27, down 6.26% today amid bearish technical signals. The stock faces selling pressure with all 13 moving averages indicating bearish momentum while oscillators remain neutral. Recent news highlights derivative-based ETF strategies and Tesla earnings implications. The company has a future dividend scheduled for June 2026.
The technical outlook appears challenging with strong bearish momentum, though the stock is trading near key support at $12. Fundamental analysis is limited due to unavailable financial ratios. Investors face volatility risks from the leveraged ETF structure and dependency on underlying Tesla performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
